| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 20002 |
| Title of Study | Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A |
| Primary Objective | To assess the effectiveness of prophylaxis with damoctocog alfa pegol in the real-world setting through the collection of total bleeding events and analysis of annualized bleeding rate (ABR) in the different prophylaxis regimens (following approved local label) in patients with hemophilia A. |
| Number of Sites | 5 |
| Period of Study | From：2021 Q1 to：2025 Q2 |
| Number of Patients | 10人 |
| IRB Approval Date | CSH 2021/1/11 TCVGH 2021/1/14 KMUH 2020/12/29 SHH Under reviewing |
| Publication Plan / Date | 2026 Q2 |
